Thorac Cardiovasc Surg 2019; 67(S 01): S1-S100
DOI: 10.1055/s-0039-1679021
Short Presentations
Tuesday, February 19, 2019
DGTHG: Auf den Punkt gebracht – End-stage Heart Failure und Assist Devices
Georg Thieme Verlag KG Stuttgart · New York

Long-Term Support of Patients Receiving a Left Ventricular Assist System for Advanced Heart Failure

J. Riebandt
1   Medical University of Vienna, Cardiac Surgery, Wien, Austria
,
D. Zimpfer
1   Medical University of Vienna, Cardiac Surgery, Wien, Austria
,
A. Fiane
2   Oslo University Hospital, Cardiothoracic Surgery, Oslo, Norway
,
R. Labalestier
3   Royal Perth Hospital, Advanced Heart Failure and Cardiac Transplant Service, Perth, Australia
,
S. Tsui
4   Department of Transplantation, Royal Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom
,
P. Jansz
5   St. Vincent’s Hospital, Heart Lung Transplant Unit, Sydney, Australia
,
A.E. Simon
6   Royal Brompton and Harefield Hospital, Department of Cardiothoracic Transplantation and Mechanical Support, Harefield Hospital, Harefield, United Kingdom
,
S. Schueler
7   Department for Cardiothoracic Surgery, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
,
J. Hanke
8   Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
,
M. Strueber
9   Beth Israel Medical Center, Cardiothoracic Surgery, Newark, United States
,
G. Dogan
8   Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
,
J. Schmitto
8   Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
28 January 2019 (online)

 
  All articles of this category

    Background: The HeartWare centrifugal flow ventricular assist device system (HVAD) is approved for treatment of advanced heart failure. The Registry to Evaluate the HeartWare Left Ventricular Assist System (ReVOLVE) is a multicenter registry that collected post-CE Mark clinical data on patients implanted with the HVAD System as a BTT in the European Union and Australia.

    The last follow-up of patients from the ReVOLVE post-CE Mark registry reported continued excellent survival of 68, 63, and 59% at 3, 4, and 5 years, respectively.

    This extended-term follow-up analysis of ReVOLVE aims to demonstrate the longest formal analysis of reliability and durability of the HeartWare ventricular assist device system.

    Methods: The ReVOLVE study is an investigator-initiated, prospective review of the HVAD in commercial use following initial CE Mark approval in 2009.

    A total of 248 patients implanted with the HVAD Pump as a left ventricular assist device at 9 centers in Europe and Australia between February of 2009 and November 2012 were included, with follow-up previously reported through January 2015. This extended follow-up will report on those patients through June 2018.

    Results: Thirty percent of patients were still alive on support with a mean follow-up of 1,464 days at the time of the last follow-up report. Extended follow-up on those patients will be reported.

    Conclusions: The paucity of donor hearts leads to longer support times for patients on LVAD support awaiting transplantation. This report will demonstrate extended survival and adverse event burden on an HVAD System.


    #

    No conflict of interest has been declared by the author(s).

       All articles of this category